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Abstract We aimed to estimate rates, causes and risk
factors of all-cause mortality in a large population-based
cohort of multiple sclerosis (MS) patients compared with
patients without MS. Using data from the UK General
Practice Research Database, we identiﬁed MS cases diag-
nosed during 2001–2006 and validated using patients’
original records where possible. We also included MS
cases during 1993–2000 identiﬁed and validated in an
earlier study. Cases were matched to up to ten referents
without MS by age, sex, index date (date of ﬁrst MS
diagnosis for cases and equivalent reference date for con-
trols), general practice and length of medical history before
ﬁrst MS diagnosis. Patients were followed up to identify
deaths; hazard ratios (HRs) and 95 % conﬁdence intervals
(CIs) were estimated using Cox-proportional regression.
MS patients (N = 1,822) had a signiﬁcantly increased risk
of all-cause mortality compared with referents
(N = 18,211); adjusted HR 1.7 (95 % CI 1.4–2.1). Com-
pared with referents, female MS patients had a higher but
not signiﬁcantly different HR for death than males;
adjusted HR 1.86 (95 % CI 1.46–2.38) vs. HR 1.31 (95 %
CI 0.93–1.84), respectively. The most commonly recorded
cause of death in MS patients was ‘MS’ (41 %), with a
higher proportion recorded among younger patients. A
signiﬁcantly higher proportion of referents than MS
patients had cancer recorded as cause of death (40 vs.
19 %). Patients with MS have a signiﬁcant 1.7-fold
increased risk of all-cause mortality compared with the
general population. MS is the most commonly recorded
cause of death among MS patients.
Keywords Multiple sclerosis  Epidemiology  Cause of
death  Cohort analysis  Mortality
Introduction
Multiple sclerosis (MS) is a chronic, progressive neuro-
logical disorder, and is the major cause of non-traumatic
disability in young adults [1]. Mortality rates are signiﬁ-
cantly higher in people with MS compared with the general
population [2–4], yet causes of death and factors inﬂu-
encing survival in MS patients are not well understood, and
further data addressing these questions are needed.
One important question is to what extent can the excess
in mortality rates observed in MS patients be attributed to
the disease. Another important question is what are the risk
factors for the disease and what inﬂuence do they have on
mortality. Identifying risk factors, and understanding their
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-014-7370-3) contains supplementary
material, which is available to authorized users.
S. S. Jick (&)  L. Li
Boston Collaborative Drug Surveillance Program,
Boston University School of Public Health,
11 Muzzey Street, Lexington, MA 02421, USA
e-mail: sjick@bu.edu
G. J. Falcone
Department of Neurology, Massachusetts General Hospital,
Boston, MA, USA
G. J. Falcone
Department of Epidemiology, Harvard School of Public Health,
Boston, MA, USA
Z. P. Vassilev
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
M.-A. Wallander
Department of Public Health and Caring Science,
Uppsala University, Uppsala, Sweden
123
J Neurol (2014) 261:1508–1517
DOI 10.1007/s00415-014-7370-3relative weight on the risk of mortality, is vital for
improving our abilities to predict survival and for imple-
menting a balanced therapeutic strategy. We therefore
aimed to estimate mortality rates, describe cause-speciﬁc
mortality and identify risk factors for mortality in a large
population-based cohort of MS patients compared with
patients without MS in the United Kingdom (UK).
Methods
Data source
We conducted a cohort study using prospectively collected
data from the UK General Practice Research Database
(GPRD). The GPRD comprises the anonymized comput-
erized medical records of around 6 % of the UK population
at any one time [5, 6]. The database is the core of the
primary care data managed by the Clinical Practice
Research Datalink (CPRD), and contains information on
patients’ demographics, clinical events, and details of
specialist referrals, hospital admissions and prescriptions.
Additional information can be added as free text. Pre-
scriptions are issued directly from the GPs computer, hence
all are recorded. Patients in the GPRD are representative of
the UK population with regard to age, sex and geographical
distribution. Validation studies have demonstrated the
quality of the data in the GPRD to be generally high [5],
and the database has been used for several studies on MS
[7–15]. The study protocol was approved by the CPRD
Independent Scientiﬁc Advisory Committee for UK Med-
icines and Healthcare products Regulatory Agency data-
base research.
Study design and MS case ascertainment
We identiﬁed a cohort of incident and prevalent MS
patients in the GPRD between January 1993 and December
2006. This was a two-step process involving two study
periods. Firstly, we identiﬁed all possible and probable
incident MS cases, and all prevalent MS cases occurring
between January 2001 and December 2006. Secondly, we
added to this 2001–2006 case set, all incident and prevalent
MS cases identiﬁed and validated in our earlier studies
conducted on the GPRD (between 1993 and 2000) [7, 8]
from practices that were still contributing to the database in
2012. To identify incident MS cases between 2001 and
2006, we identiﬁed patients registered in the GPRD in this
study period who had at least two continuous years of
registration. Patients with a ﬁrst recorded diagnosis for MS
were identiﬁed as potential incident cases, and their com-
puterized medical records were reviewed.
Potential incident cases were classiﬁed as either proba-
ble, possible, or unlikely MS using an overall clinical
impression obtained after review by a neurologist (GJF) of
all available data on diagnoses, treatments and referrals
recorded in the patient record: probable case, multiple
entries of MS diagnosis plus treatment and/or symptom
codes; possible case, at least one entry of MS diagnosis
plus codes for treatments or symptoms that may have been
related to MS or multiple MS diagnoses with no supporting
treatment or symptoms codes; unlikely case, one entry of
MS diagnosis only and no supporting treatment or symp-
toms codes, or the record contained an alternate diagnosis
such as amyotrophic lateral sclerosis.
Where available, patients’ original clinical paper records
containing clinical notes, consultation letters, specialist
referrals, test results and hospital discharge letters were
retrieved, and were reviewed by a neurologist (GJF) to
validate the MS diagnosis and classify the case. Each case
was classiﬁed according to the McDonald criteria for MS
[16] and categorized as deﬁnite, possible or unlikely. For
cases where GP comments strongly indicated that the
patient had MS but objective data were unavailable to
fulﬁll the McDonald criteria, a fourth category called
probable was used. Where there was uncertainty, a second
neurologist reviewed the patient records and a ﬁnal deci-
sion was reached by consensus. The index date was the
date of MS diagnosis.
Comparison group selection
Each case was randomly matched to up to 10 referent
subjects without a recorded diagnosis of MS at any time in
the GPRD by year of birth, sex, index date, general practice
and length of medical history recorded before the index
date. The index date for referents was the date of diagnosis
of their matched MS case.
Follow-up
Patients were followed up from the index date to identify
deaths. The end of follow-up was the date of patient’s
death, the date of transfer out of the practice, or the date
of last data collection in the database (31 July 2012),
whichever came ﬁrst. The cause of death was ascertained
from electronic and/or original clinical paper records. To
supplement information on cause of death recorded in
the GP records, we were able to link to death registry
data for patients in practices in England, and we
requested data from additional electronic GP notes where
the cause of death was unknown, but there was an
indication that additional electronic GP notes were
available.
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123Covariate information
Information on the following variables was extracted from
the database: age at ﬁrst MS diagnosis, sex, and lifestyle
factors closest to and before the ﬁrst MS diagnosis
including smoking, body mass index (BMI) and alcohol
abuse. Information on chronic comorbidities (recorded at
any time in the database), acute illnesses (recorded at or
within 1 year before diagnosis or any time after), and
comedications (at or within 6 months before diagnosis or
any time after) were also extracted. Comorbidities evalu-
ated included both chronic diseases (chronic obstructive
pulmonary disease or asthma, depression, diabetes, hyper-
tension, heart disease and cancer) and acute illnesses
[infections (respiratory, pneumonia/inﬂuenza, urinary tract,
skin, eye or ear, or other), pain (joint, spine, muscle,
migraine, eye or ear) and dyspepsia]. Comedications
evaluated included antibiotics, antidepressants, skeletal
muscle relaxants, antipsychotics, anti-Parkinson’s drugs,
anticonvulsants, opioids, non-steroidal anti-inﬂammatory
drugs (NSAIDs), topical NSAIDs, other analgesics, proton
pump inhibitors, steroids, topical steroids, statins, and oral
contraceptives. We also calculated the Charlson Comor-
bidity Index [17] before the ﬁrst recorded MS diagnosis.
We were unable to obtain information on use of interferon
beta because, in the UK, it is mostly prescribed in sec-
ondary care and is not always captured in GP records.
For the 902 MS patients with original clinical records,
we retrieved additional information on MS subtype
[relapsing-remitting MS (RRMS), primary progressive MS
(PPMS), secondary progressive MS (SPMS) or unknown],
and MS symptoms at onset. These were classiﬁed into four
main groups: sensory, motor, optic neuritis and ‘other’. The
latter group included other optic and visual anomalies,
other cranial nerve anomalies, dysarthria and asthenia.
Patients without symptoms recorded were treated as a
separate group with missing symptoms.
Statistical analyses
All deﬁnite, probable and possible MS cases were included
in the analyses. Patient characteristics were described at or
before the index date and separately at the end of follow-up
using counts [percentages (%)] for discrete and categorical
variables, and means [standard deviation (SD)] for contin-
uous variables. We compared patients’ characteristics
including lifestyle risk factors, comorbidities and comedi-
cations between the MS patients and referents. For contin-
uous variables, we used t tests; for categorical variables, we
used Chi square tests or Fisher’s exact tests where neces-
sary. Crude death rates with 95 % conﬁdence intervals (CIs)
were calculated overall and stratiﬁed by age at ﬁrst diag-
nosis, sex and type of MS. Cause of death was described
where possible. Survival probabilities for ﬁxed categorical
variables related to all-cause mortality were estimated using
Kaplan–Meier survival analyses, both overall and stratiﬁed
by age at ﬁrst diagnosis and sex. Hazard ratios (HRs) and
95 % CIs for all-cause mortality were estimated using Cox-
proportional regression models adjusted for potential con-
founding variables. Statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Between January 2001 and December 2006, 1278 incident
and 63 prevalent MS cases were identiﬁed. In addition, 435
incident and 46 prevalent MS cases identiﬁed between
1993 and 2000 were retrieved from previous studies [7–10,
12–14], giving a total of 1,822 MS cases (1,507 deﬁnite or
probable and 315 possible), matched to 18,211 referents.
Nearly, three quarters of MS cases were female and the
mean age at diagnosis was 42.1 years. PPMS patients were
generally older at diagnosis than RRMS patients (mean age
50 vs. 40 years; p\0.001), and more likely to be male
(42.4 vs. 25.1 %; p\0.001) and current smokers (32 vs.
29.4 %, p = 0.30) (Table 1). The length of follow-up post-
cohort entry date was similar for MS patients and their non-
MS comparators: 7.9 years (range 1 day–19 years).
Characteristics of MS vs. referent subjects
There were a number of signiﬁcant differences between the
characteristics, comorbidities and comedications of MS
patients and their matched referents (Tables 1, 2, 3). At the
index date, MS patients were more likely to be current
smokers (p\0.05). Within the year before the index date,
MS patients overall were more likely to have had a urinary
tract infection (p\0.05), PPMS cases were more likely to
have had an acute respiratory infection (p\0.05) and
RRMS cases were more likely to have had other infections
(p\0.05). Both RRMS and PPMS patients were more
likely to have a history of depression (p\0.05), and to
have received, antidepressants, anticonvulsants, opioids,
muscle relaxants and anti-Parkinson’s drugs at or within
the 6 months before the index date (p\0.05 for all). In
addition, during this time period, MS patients overall were
more likely to have received statins, NSAIDs, systemic
glucocorticoids, antibiotics and antipsychotics (p\0.05
for all). Compared with RRMS patients, PPMS patients
were more likely to receive symptomatic MS treatment
(e.g., muscle relaxants; 16.0 vs. 6.5 %; p = 0.0002), but
were less likely to receive antibiotics (12.8 vs. 23.3 %;
p = 0.0085).
Compared with referents, at the end of follow-up MS
patients were more likely to be smokers (26.3 vs. 22.0 %)
1510 J Neurol (2014) 261:1508–1517
123to have a BMI \18.5 kg/m
2 (3.6 vs. 2.0 %), a history of
depression (45.7 vs. 29.9 %), more infections, including
pneumonia and inﬂuenza (1.8 vs. 0.9 %), urinary tract
infections (10.5 vs. 3.9 %), and skin infections (11.9 vs.
9.8 %), and to have received more comedications in the
prior 6 months (12.3 vs. 8.5 %) (p\0.05 for all) (Online
Resource 1).
Mortality rates
Of the 1,822 MS cases, 130 (7.1 %) died during 14,295
person-years of follow-up, while 573 (3.1 %) referents died
during 144,760 person-years of follow-up. The crude death
rate for MS patients was 9.1 (95 % CI 7.6–10.8) per 1,000
person-years compared with 4.0 (95 % CI 3.6–4.3) per
1,000 person-years for the non-MS referents. Mortality
rates were higher in MS patients compared with their
matched referents in each age group and for both males and
females. Patients with PPMS had an almost twofold greater
mortality rate compared with RRMS patients (11.8 vs. 5.8
per 1,000 person-years). However, these death rates were
similarly higher compared with their corresponding refer-
ents; 6.2 vs. 2.9 per 1,000 person-years for PPMS and
RRMS referents, respectively) (Table 4).
Patients aged C50 years at diagnosis had shorter sur-
vival than those aged\50 years at diagnosis (Fig. 1). For
the latter group, an increasing difference in survival
between MS cases and their matched non-MS referents was
observed with increasing length of follow-up. Survival
probabilities were similar for both male and female MS
patients, with 10-year survival at 90 and 93 %, and 15-year
survival at 86 and 87 % for males and females,
respectively.
Cause of death
Among MS patients who died during follow-up, the most
commonly recorded cause of death was MS (40.8 %),
followed by pneumonia (25.4 %), cancer (18.5 %), car-
diovascular disease (13.9 %) and non-infectious respiratory
diseases (10.0 %). Among deceased referents, cause of
death was recorded as pneumonia in 6.8 %, cancer in
Table 1 Basic characteristics of MS cases and matched referent subjects at cohort entry, overall and stratiﬁed by type of MS
Characteristic MS cases
N = 1,822
[n (%)]
Referents
N = 18,211
[n (%)]
RRMS
a
N = 769
[n (%)]
Referents
N = 7,690
[n (%)]
PPMS
N = 125
[n (%)]
Referents
N = 1,250
[n (%)]
Mean age (years) at cohort entry (index
date; SD)
42.08 (11.79) 42.0 (11.72) 40.01 (11.14) 39.94 (11.15) 49.98 (10.43) 49.92 (10.39)
Sex
Males 481 (26.40) 4,801 (26.36) 193 (25.10) 1,930 (25.10) 53 (42.40) 530 (42.40)
Females 1,341 (73.60) 13,410 (73.64) 576 (74.90) 5,760 (74.90) 72 (57.60) 720 (57.60)
Smoking status
Current*
, 569 (31.23) 4,363 (23.96) 226 (29.39) 1,902 (24.73) 40 (32.00) 289 (23.12)
Former 239 (13.12) 2,390 (13.12) 101 (13.13) 963 (12.52) 23 (18.40) 199 (15.92)
Never 777 (42.65) 8,921 (48.99) 349 (45.38) 3,807 (49.51) 50 (40.00) 595 (47.60)
Unknown 237 (13.01) 2,537 (13.93) 93 (12.09) 1,018 (13.24) 12 (9.60) 167 (13.36)
BMI (kg/m
2)
\18.5 46 (2.52) 379 (2.08) 17 (2.21) 179 (2.33) 2 (1.60) 18 (1.44)
18.5–24.99 706 (38.75) 6,948 (38.15) 301 (39.14) 2,980 (38.75) 46 (36.80) 408 (32.64)
25.0–29.99 426 (23.38) 4,100 (22.51) 187 (24.32) 1,676 (21.79) 39 (31.20) 339 (27.12)
C30 248 (13.61) 2,406 (13.21) 112 (14.56) 993 (12.91) 12 (9.60) 198 (15.84)
Unknown 396 (21.73) 4,378 (24.04) 152 (19.77) 1,862 (24.21) 26 (20.80) 287 (22.96)
Alcohol abuse
 25 (1.37) 370 (2.03) 3 (0.39) 133 (1.73) 5 (4.0) 50 (4.0)
Mean length of recorded medical history (years; SD)
Before index date 7.86 (4.44) 7.97 (4.43) 7.93 (4.50) 8.03 (4.49) 8.83 (4.51) 9.02 (4.52)
Follow-up after index date
 7.85 (4.50) 7.95 (4.49) 8.95 (4.33) 8.18 (4.40) 8.15 (4.32) 8.15 (4.08)
For the 894 MS patients whose type of MS was determined through original clinical records
BMI body mass index, MS multiple sclerosis, PPMS primary progressive MS, RRMS relapsing-remitting MS, SD standard deviation
* p\0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)
 p\0.05 for comparison between patients with RRMS and matched referent subjects
a Includes 64 patients with secondary progressive MS
J Neurol (2014) 261:1508–1517 1511
12339.8 % and cardiovascular disease in 19.4 %. The higher
proportion of cancer deaths among referents compared
with the MS patients (p\0.0001) is noteworthy. No
material difference was found in the proportion of deaths
recorded as suicide or accident between MS patients and
referents; 1.5 and 1.9 %, respectively. However, these
proportions are based on only two MS patients (one sui-
cide) and 11 referents (two suicides). Additional data on
cause of death are provided in Online Resources 2 and 3.
Among deceased MS patients, more males than females
had their cause of death recorded as cardiovascular disease
(24.4 vs. 9.0 %, p = 0.02) or MS (43.9 vs. 39.3 %,
p = 0.62), while more females than males had cancer
recorded as cause of death (20.2 vs. 14.6 %, p = 0.45).
Patients older at diagnosis (C50 years) had a higher pro-
portion of deaths recorded as due to cancer compared with
patients diagnosed at a younger age (\50 years) (22.4 vs.
14.3 %, p = 0.23), while patients younger at diagnosis had
a higher proportion of deaths recorded as due to MS (47.6
vs. 34.3 %, p = 0.12) or pneumonia (31.8 vs. 19.4 %,
p = 0.11).
Risk factors for mortality
Compared with referents, MS patients had a signiﬁcantly
increased risk of all-cause mortality; adjusted HR 1.68
(95 % CI 1.38–2.05) (Table 5). Age was a strong effect
modiﬁer, with the youngest MS patients yielding the
highest adjusted HR 13.2 (95 % CI 4.2–41.7) for patients
aged \30 years at diagnosis. Compared with referents,
female MS patients had a higher overall HR for death than
male MS patients, although the HRs were not signiﬁcantly
different; adjusted HR 1.86 (95 % CI 1.46–2.38) vs. HR
1.31 (95 % CI 0.93–1.84). While we observed a signiﬁ-
cantly higher HR for RRMS patients compared to referents
[adjusted HR 1.50 (95 % CI 1.06–2.14)], a signiﬁcantly
Table 2 Comorbidities of MS cases and matched referent subjects at cohort entry, overall and stratiﬁed by type of MS
Characteristic MS cases
N = 1,822
[n (%)]
Referents
N = 18,211
[n (%)]
RRMS
a cases
N = 769
[n (%)]
Referents
N = 7,690
[n (%)]
PPMS cases
N = 125
[n (%)]
Referents
N = 1,250
[n (%)]
Chronic comorbidities
b
COPD and asthma 302 (16.58) 2,890 (15.87) 117 (15.21) 1,245 (16.19) 18 (14.40) 197 (15.76)
Depression*
,,§ 508 (27.88) 3,677 (20.19) 188 (24.45) 1,529 (19.88) 45 (36.00) 238 (19.04)
Diabetes 35 (1.92) 390 (2.14) 13 (1.69) 141 (1.83) 3 (2.40) 44 (3.52)
Hypertension 137 (7.52) 1,544 (8.48) 47 (6.11) 538 (7.00) 13 (10.40) 179 (14.32)
Heart disease 34 (1.87) 439 (2.41) 8 (1.04) 119 (1.55) 4 (3.20) 64 (5.12)
Cancer 50 (2.74) 558 (3.06) 15 (1.95) 223 (2.90) 5 (4.00) 50 (4.00)
Acute comorbidities
c
Acute respiratory infection
§ 252 (13.83) 2,673 (14.68) 113 (14.69) 1,143 (14.86) 9 (7.20) 171 (13.68)
Pneumonia and inﬂuenza 18 (0.99) 169 (0.93) 11 (1.43) 70 (0.91) 1 (0.80) 14 (1.12)
Urinary tract infection* 99 (5.43) 683 (3.75) 36 (4.68) 284 (3.69) 8 (6.40) 41 (3.28)
Skin infection 164 (9.00) 1,566 (8.60) 68 (8.84) 652 (8.48) 5 (4.00) 96 (7.68)
Eye or Ear infection 4 (0.22) 33 (0.18) 3 (0.39) 15 (0.20) 0 (–) 0 (–)
Other infection*
, 149 (8.18) 1,256 (6.90) 69 (8.97) 533 (6.93) 5 (4.00) 73 (5.84)
Dyspepsia 35 (1.92) 282 (1.55) 11 (1.43) 120 (1.56) 2 (1.60) 23 (1.84)
Charlson Comorbidity Index at cohort entry
Low (0) 1,393 (76.45) 14,192 (77.93) 615 (79.97) 6,048 (78.65) 96 (76.80) 931 (74.48)
Medium (1–2) 405 (22.23) 3,822 (20.99) 147 (19.12) 1,574 (20.47) 26 (20.80) 296 (23.68)
High ([2) 24 (1.32) 197 (1.08) 7 (0.91) 68 (0.88) 3 (2.40) 23 (1.84)
For the 894 MS patients whose type of MS was determined through original clinical records
COPD chronic obstructive pulmonary disorder, MS multiple sclerosis, PPMS primary progressive MS, RRMS relapsing-remitting MS
* p\0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)
 p\0.05 for comparison between patients with RRMS and matched referent subjects
§ p\0.05 for comparison between patients with PPMS and matched referent subjects
a Includes 64 patients with secondary progressive MS
b Ever before, or at cohort entry
c During the year before, or at index date
1512 J Neurol (2014) 261:1508–1517
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1.32 (95 % CI 0.69–2.55)]. It should be noted, however,
that the number of PPMS patients was small.
Discussion
This large study of 1,822 people with MS in UK primary
care provides national estimates of all-cause mortality
among this patient group. We observed a 1.7-fold increased
risk of all-cause mortality for MS patients compared with
the general population. This increase in risk is in line with
reports from other large population-based cohorts [2–4,
18–21], although direct comparisons are difﬁcult owing to
differences in geographical regions and/or study periods.
Consistent with other reports, MS was the main recorded
cause of death (40.8 %) in MS patients in our study. This
proportion is lower than that in other studies, albeit from a
wide range of geographical populations, where MS was the
reported cause of death in more than 50 % of affected
patients [4]. Respiratory diseases, infections, cardiovascu-
lar diseases and cancers are other commonly reported
causes of death in patients with MS [2, 22], and our results
are consistent with these ﬁndings. It should be noted that
the ‘‘real’’ causes of death in patients with MS are not
always recorded in patient records or registries. While it is
accepted that MS is not per se a fatal disease, neither our
study nor prior studies have been able to identify all direct
causes of death in these patients. Thus, complete infor-
mation on cause of death remains unattainable. The lower
proportion of MS patients with cancer as the cause of death
compared to non-MS referents could be due to increased
susceptibility to acute causes of death (such as infections or
acute cardiovascular events). These acute and sometimes
fatal comorbidities may act as competing risks, truncating
the long latency periods needed for a neoplastic disease to
express clinically. Current evidence suggests that fre-
quency of suicides may be higher in MS patients [23]. In
only three patients was suicide the recorded cause of death
in our study (one MS patient and two referents), which was
insufﬁcient to detect any material difference between the
patient groups.
The progressive nature of MS is reﬂected in our study in
the increasing differences in all-cause mortality rates seen
between MS patients and their matched non-MS referents
with increasing length of follow-up. It is interesting that all
HRs were attenuated when risk factors for comedications
associated with MS were included in the model. This
suggests that some of the increased risk for death is asso-
ciated with the comorbidities and resulting comedications
Table 3 Comedications of MS cases and matched referent subjects at cohort entry, overall and stratiﬁed by type of MS
Characteristic All MS cases
N = 1,822
[n (%)]
Referents
N = 18,211
[n (%)]
RRMS
a cases
N = 769
[n (%)]
Referents
N = 7,690
[n (%)]
PPMS cases
N = 125
[n (%)]
Referents
N = 1,250
[n (%)]
Comedications (at cohort entry [index date] or within the 6 months before)
Systemic
glucocorticoids*
,
180 (9.88) 713 (3.92) 69 (8.97) 288 (3.75) 8 (6.40) 52 (4.16)
Antidepressants*
,,§ 380 (20.86) 1,582 (8.69) 132 (17.17) 662 (8.61) 28 (22.40) 102 (8.16)
Anticonvulsants*
,,§ 122 (6.70) 225 (1.24) 40 (5.20) 88 (1.14) 11 (8.80) 25 (2.00)
Antidiabetics 24 (1.32) 283 (1.55) 12 (1.56) 112 (1.46) 0 (–) 30 (2.40)
Opioids*
,,§ 345 (18.94) 1,585 (8.70) 122 (15.86) 621 (8.08) 23 (18.40) 133 (10.64)
NSAIDs*
, 316 (17.34) 1,806 (9.92) 122 (15.86) 710 (9.23) 21 (16.80) 152 (12.16)
Statins* 61 (3.35) 447 (2.45) 20 (2.60) 137 (1.78) 4 (3.20) 75 (6.00)
Antibiotics*
, 403 (22.12) 3,598 (19.76) 179 (23.28) 1,546 (20.10) 16 (12.80) 227 (18.16)
Muscle relaxants*
,,§ 173 (9.50) 399 (2.19) 50 (6.50) 153 (1.99) 20 (16.00) 37 (2.96)
Antipsychotics*
, 122 (6.70) 387 (2.13) 54 (7.02) 160 (2.08) 5 (4.00) 20 (1.60)
Anti-Parkinson drugs*
,,§ 23 (1.26) 54 (0.30) 8 (1.04) 17 (0.22) 3 (2.40) 4 (0.32)
PPIs* 83 (4.56) 657 (3.61) 24 (3.12) 243 (3.16) 6 (4.80) 68 (5.44)
For the 894 MS patients whose type of MS was determined through original clinical records
MS multiple sclerosis, NSAIDs non-steroidal anti-inﬂammatory drugs, PPMS primary progressive MS, PPIs proton pump inhibitors, RRMS
relapsing-remitting MS
* p\0.05 for comparison between patients with MS and matched referent subjects (for all MS patients)
 p\0.05 for comparison between patients with RRMS and matched referent subjects
§ p\0.05 for comparison between patients with PPMS and matched referent subjects
a Includes 64 patients with secondary progressive MS
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123that occur more frequently in patients with MS. It is
notable that the HRs for death in the MS cohort compared
to the non-MS cohort were highest in the younger patients
and decreased with increasing age. It is possible that the
decreased baseline risk of death in younger people con-
tributed to the higher HR, while baseline risks increased for
all patients with increasing age leading to lower HRs. We
did not, however, ﬁnd any statistically signiﬁcant differ-
ence in survival between males and females, although the
adjusted HR for all-cause mortality was higher for females.
Other reports concerning gender difference in survival
have been mixed [2, 4, 18, 19].
MS patients in this study were more likely to have been
diagnosed with depression in the period between ﬁrst MS
symptoms and ﬁrst MS diagnosis. Diagnoses of depression
in the years before ﬁrst symptoms were similar in the MS
patients and their matched non-MS referents. Given their
timing, these ﬁndings can be interpreted either as ‘‘reac-
tive’’ in the setting of a neurological disease of uncertain
etiology, or as a direct result of neural damage caused by
the ongoing inﬂammatory process affecting the CNS. In
any case, these results highlight that depression, together
with the heavy burden it imposes on functional status,
becomes a relevant problem in MS subjects long before a
ﬁnal diagnoses of MS can be reached. The higher incidence
of urinary tract infection in the months prior to MS diag-
nosis is consistent with decreased mobility found in MS
patients, particularly those with PPMS. While the inci-
dence of Parkinson’s disease was higher in the MS group
compared to the non-MS referents, the absolute number of
Table 4 Death rate per 1,000
person-years in patients with
MS and matched referent
subjects overall, stratiﬁed by
age at ﬁrst diagnosis of MS, sex,
and type of MS
CI conﬁdence interval, MS
multiple sclerosis, RRMS
relapsing-remitting MS, PPMS
primary progressive MS
a For the 894 MS cases
conﬁrmed by original clinical
records
b Including 64 patients with
SPMS
Deaths (N) Population size Person-years Death rates (95 % CI)
Overall
Patients with MS 130 1,822 14,295 9.09 (7.63–10.76)
Referent subjects 573 18,211 144,760 3.96 (3.64–4.29)
Age group at diagnosis (years)
\30
Patients with MS 8 264 1,996 4.01 (1.86–7.61)
Referent subjects 5 2,666 18,857 0.27 (0.10–0.59)
30–39
Patients with MS 20 522 4,036 4.96 (3.11–7.52)
Referent subjects 48 5,217 40,721 1.18 (0.88–1.55)
40–49
Patients with MS 35 564 4,600 7.61 (5.38–10.46)
Referent subjects 116 5,634 47,483 2.44 (2.03–2.92)
50–59
Patients with MS 30 338 2,744 10.93 (7.51–15.41)
Referent subjects 180 3,380 27,643 6.51 (5.61–7.52)
C60
Patients with MS 37 134 919 40.26 (28.76–54.91)
Referent subjects 224 1,314 10,057 22.27 (19.50–25.34)
Sex
Male
Patients with MS 41 481 3,717 11.03 (8.02–14.82)
Referent subjects 228 4,801 37,284 6.12 (5.36–6.95)
Female
Patients with MS 89 1,341 10,578 8.41 (6.80–10.30)
Referent subjects 345 13,410 107,476 3.21 (2.88–3.56)
Type of MS
RRMS
Patients with MS 40 769
a,b 6,881 5.81 (4.21–7.84)
Referent subjects 183 7,690 62,928 2.91 (2.51–3.35)
PPMS
Patients with MS 12 125
a 1,018 11.79 (6.39–20.04)
Referent subjects 63 1,250 10,184 6.19 (4.79–7.86)
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123cases was small. Previous reports have not found similar
differences. It is possible that at least some of the 23 cases
had Parkinsonian symptoms due to compromise of the
basal ganglia by the underlying neuro-inﬂammatory pro-
cess, but were misdiagnosed and treated as idiopathic
Parkinson’s disease. Alternatively, the association could be
explained by unmeasured confounders.
Strengths of our study include the large sample size, the
high quality of the database and the controlled study
design. The representativeness of the study population
means that the results can be generalized to the UK as
whole, thus the study has high external validity. In addi-
tion, for some MS cases, we were able to validate the
diagnosis by accessing patients’ original clinical records,
which along with linkage to death registry data, enabled
additional clinical information to be obtained. We were
also able to obtain and analyze data on a large number of
potential risk factors for mortality.
Our study also has limitations. We were unable to val-
idate the MS diagnosis via original clinical records for all
patients, thus it is likely that some misclassiﬁcation of MS
cases occurred. Any misclassiﬁcation would likely have
been random, non-differential, and would have had little
effect on the mortality rates in the study. Any effects on the
HRs would likely have been small and biased toward the
null. However, when we repeated the main analyses for
cases whose diagnosis was made on original clinical
records and for cases whose diagnosis was made from
electronic records only, we found the results from the two
groups to be consistent. When we repeated the analyses
again, restricted to deﬁnite and probable MS patients, the
results were similar to the full group analysis (Online
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Fig. 1 a Kaplan–Meier plot for
the survival probabilities (all-
cause mortality) of patients
\50 years at index date. MS
multiple sclerosis. b Kaplan–
Meier plot for the survival
probabilities (all-cause
mortality) of patients C50 years
at index date. MS multiple
sclerosis
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123Resources 4–7). We were also unable to identify cause of
death for around 15 % of deceased MS patients and 17 %
of deceased referents, which may have inﬂuenced com-
parisons of cause of death. However, we found the most
common causes of deaths were consistent with those
reported elsewhere [22]. Our study was underpowered to
explore risk factors for cause-speciﬁc mortality, and it is
also possible that there was some underestimation of our
reported all-cause mortality rates. This is because follow-
up time may not have been long enough to observe mor-
tality, especially for MS cases identiﬁed between 2001 and
2006. It is also possible that a small number of deaths were
not recorded by the GP though recording of death is
required of all GPs and this number should be minimal. In
addition, we were unable to evaluate the inﬂuence of
interferon beta, which has been shown to slow disease
progression [24–26] and reduce all-cause mortality [26–28]
in patients with RRMS. Although this may have affected
our estimates of all-cause mortality among RRMS patients,
it is unlikely to have affected the HRs associated with
factors found to be predictive of all-cause mortality, as
such confounding by indication is unlikely.
In summary, our ﬁndings show that patients with MS
have increased all-cause mortality rates compared with the
general population, and that some of this increase is likely
related to the comorbidities that occur more frequently in
patients with MS. Most deaths in MS patients are recorded
as due to the disease itself.
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Table 5 Hazard ratios and 95 % conﬁdence intervals for all-cause mortality among MS cases versus matched referent subjects
Characteristic Death in MS patients
N = 130 [n (%)]
Deaths in non-MS referents
N = 573 [n (%)]
HR (95 % CI)
Model 1
a Model 2
b
Overall 130 (100) 573 (100) 2.30 (1.90–2.78) 1.68 (1.38–2.05)
Age at ﬁrst MS diagnosis (years)
\30 8 (6.2) 5 (0.87) 14.19 (4.62–43.54) 13.18 (4.17–41.67)
30–39 20 (15.4) 48 (8.4) 4.27 (2.53–7.19) 3.29 (1.93–5.61)
40–49 35 (26.9) 116 (20.2) 3.13 (2.15–4.57) 2.16 (1.45–3.21)
50–59 30 (23.1) 180 (31.4) 1.66 (1.13–2.44) 1.33 (0.88–1.99)
C60 37 (28.5) 224 (39.1) 1.82 (1.28–2.57) 1.47 (1.03–2.12)
Sex
Male 41 (31.5) 228 (39.8) 1.79 (1.28–2.49) 1.31 (0.93–1.84)
Female 89 (68.5) 345 (60.2) 2.63 (2.09–3.32) 1.86 (1.46–2.38)
Type of MS
c
RRMS
d 40 (30.8) 183
e (31.9) 1.94 (1.38–2.73) 1.50 (1.06–2.14)
PPMS 12 (9.2) 63
f (11.0) 1.89 (1.02–3.51) 1.32 (0.69–2.55)
CI conﬁdence interval, HR hazard ratio, MS multiple sclerosis, PPMS primary progressive MS, RRMS relapsing-remitting MS, SPMS secondary
progressive MS
a Adjusted for matching variables (age, sex, index date, GP, and length of medical history recorded before the index date)
b Adjusted for smoking and comedications (including antidepressants, anticonvulsants, opioids, muscle relaxants) within 6 months before or at
the index date, in addition to the matching variables
c MS cases conﬁrmed by original clinical paper records
d Including patients with SPMS
e Matched to patients with RRMS
f Matched to patients with PPMS
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